These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8059228)

  • 1. Tissue factor pathway inhibitor.
    Novotny WF
    Semin Thromb Hemost; 1994; 20(1):101-8. PubMed ID: 8059228
    [No Abstract]   [Full Text] [Related]  

  • 2. Tissue factor pathway inhibitor: a potent inhibitor of in-vitro coagulation and in-vivo thrombus formation.
    Lindahl AK
    Curr Opin Lipidol; 1994 Dec; 5(6):434-9. PubMed ID: 7712048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of tissue factor and its inhibitor in hemostasis].
    Naumnik B; Małyszko J; Myśliwiec M
    Przegl Lek; 1998; 55(2):68-73. PubMed ID: 9695646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA.
    Anderson S; Cohen AT; Melissari E; Scully MS; Kakkar VV
    Thromb Haemost; 1995 Feb; 73(2):328-9. PubMed ID: 7792754
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue factor pathway inhibitor and antithrombin trial results.
    LaRosa SP; Opal SM
    Crit Care Clin; 2005 Jul; 21(3):433-48. PubMed ID: 15992666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits.
    Bregengaard C; Nordfang O; Ostergaard P; Petersen JG; Meyn G; Diness V; Svendsen O; Hedner U
    Thromb Haemost; 1993 Sep; 70(3):454-7. PubMed ID: 8259548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor pathway inhibitor.
    Camici M; Sagripanti A
    Minerva Med; 1999; 90(1-2):25-32. PubMed ID: 10388460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue factor pathway inhibitor (TFPI).
    Rucińska M; Gacko M; Skrzydlewski Z
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():118-22. PubMed ID: 9337530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced tissue factor pathway inhibitor-1 after pharmacological thrombolysis: an epiphenomenon or potential culprit in rethrombosis?
    Shah PK
    Circulation; 2002 Jan; 105(3):270-1. PubMed ID: 11804975
    [No Abstract]   [Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor: clinical deficiency states.
    Sandset PM; Bendz B
    Thromb Haemost; 1997 Jul; 78(1):467-70. PubMed ID: 9198198
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
    Alban S
    Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits.
    Warn-Cramer BJ; Maki SL; Rapaport SI
    Thromb Haemost; 1993 Mar; 69(3):221-6. PubMed ID: 8470044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions involving oral anticoagulants.
    O'Reilly RA
    Cardiovasc Clin; 1974; 6(2):23-41. PubMed ID: 4613460
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
    Li A; Chang AC; Peer GT; Wun TC; Taylor FB
    Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
    Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
    Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant therapy in acute lung injury.
    Laterre PF; Wittebole X; Dhainaut JF
    Crit Care Med; 2003 Apr; 31(4 Suppl):S329-36. PubMed ID: 12682461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
    Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue factor pathway inhibitor: potential therapeutic applications.
    Bajaj MS; Bajaj SP
    Thromb Haemost; 1997 Jul; 78(1):471-7. PubMed ID: 9198199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
    Brown JR; Kuter DJ
    Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.